Observational study found higher infection rates in patients with lymphoma and myeloma treated with bispecific antibodies, indicating a need for improved prophylaxis.
Key Points
To describe the incidence and risk factors for infections in patients receiving T-cell engaging bispecific antibodies.
Identified patients with r/r B-cell non-Hodgkin lymphoma or multiple myeloma treated with BsAbs from institutional databases.
Collected baseline, treatment, and outcome data.
Analyzed associations using Wilcoxon rank sum test and Fisher's exact test.
200 patients identified: 56 with NHL and 144 with MM.
113 patients (57%) had one or more infections during or after treatment.
10%+ of patients experienced grade ≥ 3 infections, with some deaths related to infections.